NCT02089438

DPP-4 Inhibition, Incretins and Islet Function

Comparison of Three DPP-4 Inhibitors on 24 Hour Blood Glucose, Incretin Hormones and Islet Function in Patients With Type 2 Diabetes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Lund University · Academic / Other
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Hypothesis is that DPP-4 inhibition affects glucose levels through changes in incretin and islet hormones. The study examines this in relation to breakfast, lunch and dinner over an entire 24h study period by the use of three different DPP-4 inhibitors and placebo.

Detailed description

The study is a single-center study with a cross-over design to examine glycemia, incretin hormones and islet hormones over a 24h study period with standardized breakfast, lunch and dinner after administration of placebo, saxagliptin, vildagliptin or sitagliptin.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Saxagliptin	Saxagliptin (5 mg) is given before breakfast
DRUG	Vildagliptin	Vildagliptin (50mg) is given before breakfast and dinner
DRUG	Sitagliptin	Sitagliptin (100 mg) is given before breakfast

Timeline

• Start date: 2014-05-01
• Primary completion: 2017-06-01
• Completion: 2017-08-01
• First posted: 2014-03-17
• Last updated: 2017-08-23

Locations

1 site across 1 country: Sweden